Fate and Celyad’s CAR therapies in oncology offer potential to amplify efficacy with multiple doses
Experts saw potential in CAR NKs like FT596 or CAR T-cell products engineered to express NKG2D like CYAD-101. Credit: CI Photos/Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more